Home Endocrinology & Hormones Endogenous Metabolite inhibitor - Wnt/beta-catenin modulator Heparan Sulfate

research use only

Heparan Sulfate Linear Polysaccharide

Cat.No.S5992

Heparan sulfate (HS, Heparitin sulfate, Alpha-idosane, HHS 5, N-Acetylheparan Sulfate, Suleparoid, Tavidan), a constituent of HS proteoglycans (HSPGs), is a linear polysaccharide present on the cell surface. Heparan sulfate influences the binding affinity of intestinal epithelium cells (IECs) to Wnt, thereby promoting activation of canonical Wnt signaling and facilitating regeneration of small intestinal crypts after epithelial injury.
Heparan Sulfate Endogenous Metabolite inhibitor Chemical Structure

Chemical Structure

Molecular Weight:

Jump to Mechanism of Action Solubility Chemical Information, Storage & Stability

Quality Control

Chemical Information, Storage & Stability

Molecular Weight Formula

--

 Storage (From the date of receipt) 3 years -20°C powder
CAS No. 9050-30-0 -- Storage of Stock Solutions

Solubility

In vitro
Batch:

Water : 100 mg/mL

DMSO : Insoluble
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Ethanol : Insoluble

Molarity Calculator

Mass Concentration Volume Molecular Weight

In vivo
Batch:

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Mechanism of Action

Targets/IC50/Ki
Wnt [1]
References

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2024-05-22)

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT06052423 Withdrawn
Extensive Stage Small Cell Lung Cancer (ES-SCLC)
Hansoh BioMedical R&D Company
 November 30 2024 Phase 2
NCT05928078 Not yet recruiting
Cognitive Decline
University of Castilla-La Mancha
 September 1 2024 Not Applicable
NCT06208735 Not yet recruiting
B-Cell Leukemia|Non-Hodgkin''s Lymphoma|B-cell Acute Lymphoblastic Leukemia|Diffuse Large B Cell Lymphoma|High-grade B-cell Lymphoma|Primary Mediastinal Large B-cell Lymphoma (PMBCL)|Mantle Cell Lymphoma|B-cell Lymphoma
British Columbia Cancer Agency
 July 1 2024 Phase 1
NCT05470322 Not yet recruiting
Hidradenitis Suppurativa|Scarring
Montefiore Medical Center
 June 2024 Not Applicable
NCT06118281 Not yet recruiting
Cardiovascular Risk|Acute Myocardial Infarction (AMI)
Novo Nordisk A/S|Duke Clinical Research Institute
 June 25 2024 Phase 3

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.